Clever Culture Systems (CC5) H1 2026 earnings summary

Executive summary

• Revenue for the half year ended 31 December 2025 was $2.56 million, down 32% year-over-year, mainly due to the absence of $0.91 million in government grants and other income received in the prior period.

• Net loss after tax was $1.32 million, compared to a profit of $1.11 million in the prior period, driven by higher employee expenses, increased non-cash costs, and lower grant income.

• Cash position increased to $3.1 million, supported by $3.2 million from exercised options and full repayment of a $1 million government loan, leaving the company debt-free.

• Net tangible assets per share rose to 0.22 cents from 0.16 cents at 30 June 2025.

Financial highlights

• Revenue: $2.56 million (down from $3.77 million year-over-year).

• Net loss after tax: $1.32 million (vs. $1.11 million profit prior year).

• Cash and cash equivalents: $3.1 million at 31 December 2025.

• Net assets increased by $2.4 million to $8.0 million.

• No dividend declared or paid.

Outlook and guidance

• Focus remains on expanding the customer base among global pharmaceutical manufacturers and executing the “land and expand” strategy.

• Additional placements and customer evaluations expected in the next 12 months, aiming to drive recurring revenues and long-term growth.

• Continued investment in technology enhancements and customer support to facilitate adoption and recurring revenue streams.